A monoclonal-antibody drug reduced hospitalizations or death from Covid-19 by 85% compared with a placebo in a clinical trial, said Vir Biotechnology and GlaxoSmithKline, the drug’s developers.

The antibody drug reduced the risk of developing symptomatic Covid-19 infection by 81% compared with a placebo in people living with someone infected by the new coronavirus, a study found.

In response to the ongoing COVID-19 pandemic, a new study conducted by researchers at Yale and the University of British Columbia found that a lower-than-recommended dose of a common COVID-19 ...

Jan. 26, 2022 — The drugs behind the new pills to treat COVID-19 remain very effective against the omicron variant of the virus in lab tests, according to a new study. However, lab tests also ...

Topline. Paxlovid—Pfizer’s antiviral Covid-19 treatment—is 37% effective at preventing hospitalization or death in high-risk patients compared with no treatment, according to a study ...

New additions and recent updates; Aug. 6: An N.I.H. study showed that lenzilumab performed no better than a placebo.: July 8: Added the anti-cancer drug sabizabulin.: May 10: The F.D.A. approves ...

A new drug being developed by Pfizer offers the possibility of nearly putting an end to deaths from COVID-19.. When given within five days of the onset of symptoms, the antiviral therapy, called ...

McMaster University researchers are leading a large international study to test drugs to treat COVID-19 patients. The trial will evaluate the effectiveness of ivermectin, metformin and fluvoxamine ...

COVID-19 therapies made from a cocktail of two types of antibodies were effective against a wide range of variants of the coronavirus in a mice and hamster study, the Washington University School ...

An experimental drug prevented half of severe coronavirus infections that would otherwise have sent COVID-19 patients to the hospital, a study shows. Hotspots ranked Start the day smarter ☀️ ...